Welcome to our dedicated page for Cresco Labs news (Ticker: CRLBF), a resource for investors and traders seeking the latest updates and insights on Cresco Labs stock.
Cresco Labs Inc. (CRLBF) operates at the forefront of medical cannabis cultivation and regulatory compliance. This dedicated news hub provides investors and industry observers with timely updates on corporate developments, financial disclosures, and operational milestones.
Access official press releases alongside curated analysis covering earnings reports, partnership announcements, and regulatory achievements. Our aggregation ensures you stay informed about CRLBF's progress in expanding cultivation capacity, maintaining quality standards, and navigating evolving cannabis legislation.
Key content includes updates on production innovations, patient-focused initiatives, and strategic market expansions. Bookmark this page for streamlined tracking of Cresco Labs' performance in the competitive medical cannabis sector.
Cresco Labs (OTCQX:CRLBF) continues its expansion in Florida with the opening of a new Sunnyside dispensary at 8717 SW 24th St., Miami, enhancing its retail presence to 29 locations statewide and 64 nationwide. The new facility aims to serve the growing patient base in Miami-Dade, the eighth most populous county in the U.S. with nearly 2.7 million residents. The store offers a broad range of cannabis products from Cresco's branded portfolio, including Cresco, One Plant, and Good News. CEO Charlie Bachtell emphasizes the company's commitment to reaching more patients in populous regions. The store operates Monday to Saturday from 9 AM to 8 PM and Sunday from 9 AM to 6 PM, allowing for both in-store and online orders.
Cresco Labs reported annual revenues of $843 million for 2022, marking a 3% year-over-year increase. Excluding exited California operations, adjusted revenues grew 6%. The company achieved a record 61 million branded units sold and 4.6 million retail transactions, up 37% and 15% respectively. Despite a $215 million net loss due to $141 million in impairment charges, Cresco generated positive operating cash flow of $19 million. The fourth quarter saw a revenue decline of 8% year-over-year, with adjusted gross profit at $90 million. Management remains focused on optimizing operations and maintaining leadership in branded cannabis products.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) has expanded its retail presence in Florida, opening new dispensaries in Palm Harbor and Lake Worth, increasing its total Florida footprint to 28 dispensaries and nationwide store count to 63. This growth follows Cresco's achievement of serving nearly one million customers at its Sunnyside stores this year, driven by a diverse product offering and excellent customer service. The new locations will support local patient communities by providing a wide range of cannabis products.